Register Login

Instil Bio Inc (TIL)

  • Event
  • Oct. 18, 2022, 21:01 UTC

(10% Negative) Instil Bio, Inc. (TIL) Announces Delay in patients Trials for cancer Due to Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 3, 2025, 9:28 a.m.

    📋 Instil Bio, Inc. (TIL) - Clinical Trial Update

    Filing Date: 2022-10-18

    Accepted: 2022-10-18 17:01:47

    Event Type: Clinical Trial Update

    Event Details:

    Instil Bio Inc (TIL) Announces Clinical Trial Update Instil Bio Inc (TIL) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: patients, expected
    • Diseases/Conditions: cancer
    • Clinical Stage: NCT05397093, Phase 1
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Regulatory Process
    • Collaboration: TIL
      • expected in 2023
      • Targeting Folate Receptor Alpha (FRα), in Non-Small Cell Lung Cancer–ITIL-306 is a novel TIL therapy engineered with our CoStAR platform (CoStAR-TIL) targeting folate receptor alpha which is designed to boost TIL activity in the tumor microenvironment–CoStAR-T cells demonstrate enhanced proliferation and other effector function, which may increase TIL efficacy and eliminate the need for high-dose interleukin-2–Patient with non-small cell lung cancer that is refractory to standard therapies is first to receive ITIL-306–Initial clinical data from dose escalation cohorts expected in 2023

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Instil Bio Inc
    • CIK: 0001789769
    • Ticker Symbol: TIL
    • Period End Date: 2022-10-18
    • Document Type: 8-K

Search

News categories